Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies

The companies will explore the use of MGTA-117, which is currently in preclinical IND-enabling studies as a conditioning regimen for patients receiving gene therapy designed to be less toxic than the current standard of chemotherapy or radiation.